Navigation Links
Clarus Ventures Closes $660 Million Fund
Date:2/25/2008

Brings assets under management to $1.2 billion

CAMBRIDGE, Mass. & SOUTH SAN FRANCISCO, Calif., Feb. 25 /PRNewswire/ -- Clarus Ventures, LLC ("Clarus Ventures"), a leading life sciences venture capital firm, announced today the single close of Clarus Lifesciences II, L.P. ("Clarus II"), a $660 million fund in Limited Partner commitments. This is the second investment fund formed and managed by Clarus Ventures, since the firm was established in 2005.

Clarus II will invest $20-60 million in biotechnology, specialty pharmaceutical and medical technology companies that are developing innovative products for the treatment of human diseases. The firm's first fund has committed 90 percent of its proceeds to date.

"We have effectively completed the deployment of our first fund and built a diversified portfolio of exciting companies," said Robert Liptak, a Clarus Ventures Managing Director. "These include companies with strong growth in revenue and profitability such as Globus Medical; products near commercialization such as Sientra, Pelikan, Oxford and Zogenix; and those with breakthrough products and technologies such as Aerovance, Centaurus, CoMentis, ESBATech, Pearl, ProActa, SarCode, Taligen, and Variation. We plan to follow a similar investment strategy for Clarus II. With the diversity and depth of our team we believe we can leverage our experience to identify and help grow leading companies in the life sciences field."

The Limited Partner base for Clarus II was effectively the same as in Clarus I. A small, select group of new high-quality investors who knew the firm well also participated.

The Clarus Ventures team is led by Nicholas Galakatos, Dennis Henner, Jeffrey Leiden, Robert Liptak, Nicholas Simon, Michael Steinmetz and Kurt Wheeler, an established group of investment professionals with deep and complementary backgrounds within the life sciences industry. The team uniquely balances broad investing expertise with leadership experience in major biotechnology and pharmaceutical companies.

About Clarus Ventures

Founded by a group of accomplished investment professionals with extensive and complementary industry backgrounds, Clarus Ventures is a life sciences venture capital firm with a team that has a long history of success in creating value. Internal operating experience combined with longstanding relationships with key opinion leaders and industry thought leaders and decision makers allow this team to identify unique investment opportunities and shepherd them to maturity. Clarus Ventures augments its core expertise of investing in biopharmaceuticals and medical technology with deep and diverse expertise in research and development, commercialization, business development and operations management at the global level. The firm has $1.2 billion under management and has offices in Cambridge, Mass., and South San Francisco, CA.

For additional information on Clarus Ventures, please visit http://www.clarusventures.com.

CONTACTS:

Nicholas Galakatos, Ph.D., Clarus Ventures, Tel.: 617-949-2223

Robert Liptak, Clarus Ventures, Tel.: 617-694-2222

Tony Russo, Russo Partners, Tel.: 212-845-4251


'/>"/>
SOURCE Clarus Ventures, LLC
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. 5AM Ventures Announces Expansion of Investment Team: Names Richard Ulevitch Venture Partner; Promotes Kevin Forrest and Andrew McMillan to Principal
2. Jerusalem Global Ventures Announces $200 Million Growth Equity Fund
3. Khosla Ventures and BIOeCON Form KiOR Inc.
4. Vivo Ventures Expands Team with the Addition of James Huang as an Executive in Residence
5. Corium International, Inc., Announces $40 Million Financing led by Essex Woodlands Health Ventures
6. Dan Broderick Joins Prolog Ventures as Partner
7. Hank Plain Joins Morgenthaler Ventures as Partner
8. Ocera Therapeutics Closes $35.5 Million Series C Financing
9. Sinovac Closes $9.75 Million Private Placement
10. MiddleBrook Pharmaceuticals Closes Private Placement of Common Equity Raising $21 Million
11. Progentix Orthobiology B.V. Closes Series A Financing Round
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2017)... SAN FRANCISCO , Sept. 19, 2017 ... Management Solutions (VLMS) is pleased to announce the strategic ... VTI to provide clients with validation services using the ... a partner, VTI will provide clients with efficient and ... be a marketing partner for the ValGenesis VLMS system. ...
(Date:9/18/2017)... ... September 18, 2017 , ... Transportable biomass conversion ... and torrefied wood is the topic of a September 27 webinar ... economic viability of transportable biomass conversion facilities for producing biochar, briquettes, and torrefied ...
(Date:9/15/2017)... ... September 15, 2017 , ... ... it calls an ‘Internal Seed B’ round of financing, totaling $600,000. The ... completed using a ‘SAFE’ documentation structure at a company valuation of $10M. ...
(Date:9/14/2017)... ... September 14, 2017 , ... AxioMed ... case in Australia. Dr. Steven Yang completed the procedure on a 35-year-old female ... a degenerative lumbar disc at level L5-S1. The patient failed conservative treatments prior ...
Breaking Biology Technology:
(Date:4/5/2017)... LONDON , April 4, 2017 KEY ... is anticipated to expand at a CAGR of 25.76% ... neurodegenerative diseases is the primary factor for the growth ... full report: https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The ... of product, technology, application, and geography. The stem cell ...
(Date:3/30/2017)... March 30, 2017 Trends, opportunities and forecast ... behavioral), by technology (fingerprint, AFIS, iris recognition, facial recognition, ... others), by end use industry (government and law enforcement, ... and banking, and others), and by region ( ... Asia Pacific , and the Rest ...
(Date:3/24/2017)... Research and Markets has announced the addition ... Trends - Industry Forecast to 2025" report to their offering. ... The Global Biometric ... of around 15.1% over the next decade to reach approximately $1,580 ... market estimates and forecasts for all the given segments on global ...
Breaking Biology News(10 mins):